share_log

BioAffinity Technologies (NASDAQ:BIAFW) Stock Price Down 14.7%

Defense World ·  Apr 12, 2023 03:53

bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating)'s stock price was down 14.7% during mid-day trading on Tuesday . The stock traded as low as $0.26 and last traded at $0.26. Approximately 611 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 5,024 shares. The stock had previously closed at $0.31.

bioAffinity Technologies Trading Down 14.7 %

The firm has a fifty day moving average of $0.35 and a 200 day moving average of $0.40.

Get bioAffinity Technologies alerts:

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Armistice Capital LLC purchased a new position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 204,082 shares of the company's stock, valued at approximately $72,000.

About bioAffinity Technologies

(Get Rating)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.

See Also

  • Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAFW)
  • Weight Watchers Reshapes Itself with a Game-Changer Acquisition
  • Two Tiny Mining Stocks Worth Considering for the Next Gold Rush
  • Nano Dimension Prints Growth: Enters Hypergrowth Phase
  • CF Is Set To Harvest The Bull Run In Agricultural Stocks
  • Oracle Dips But The Trend Is Strong

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment